Supernus Pharmaceuticals, Inc.: all 86 studies

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderRecruitingNCT07226661Phase 2
• Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:RecruitingNCT07219927
• SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresRecruitingNCT07141329Phase 2
• RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresRecruitingNCT06798896Phase 2
• Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant EpilepsyRecruitingNCT05518578Phase 2
• Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHDRecruitingNCT04781140Phase 4
• Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating WomenCompletedNCT06259331Phase 4Results posted
• Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood SymptomsCompletedNCT06185985Phase 4Results posted
• A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseaseTerminatedNCT05655520Phase 3Results posted
• An Open-Label Study Evaluating Brexanolone in Adults With TinnitusCompletedNCT05645432Phase 2Results posted
• A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)CompletedNCT05619692Phase 2Results posted
• A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential TremorTerminatedNCT05366751Phase 2/3Results posted
• 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's DiseaseCompletedNCT05358821Phase 2Results posted
• A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive ImpairmentCompletedNCT05318937Phase 2Results posted
• Study to Evaluate SAGE-324 in Participants With Essential TremorCompletedNCT05173012Phase 2Results posted
• A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)CompletedNCT05107128Phase 2Results posted
• A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home SettingCompletedNCT05059600Phase 4Results posted
• Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb SpasticityTerminatedNCT04815967Phase 2/3Results posted
• Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHDCompletedNCT04786990Phase 4Results posted
• A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)CompletedNCT04602624Phase 2Results posted
• A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)TerminatedNCT04537806Phase 3Results posted
• A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)CompletedNCT04476017Phase 2Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential TremorCompletedNCT04305275Phase 2Results posted
• Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHDCompletedNCT04143217Phase 3Results posted
• Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb SpasticityTerminatedNCT04099667Phase 2/3Results posted
• Therapy for Migraine Prevention in Children 6-11 Years of AgeTerminatedNCT04050293Phase 4Results posted
• Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHDCompletedNCT04016779Phase 3Results posted
• Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)CompletedNCT03944785Results posted
• A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)CompletedNCT03665038Phase 3Results posted
• Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHDTerminatedNCT03638466Phase 2Results posted
• Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD TreatmentTerminatedNCT03597503Phase 3Results posted
• A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking ImpairmentCompletedNCT03567057Phase 3Results posted
• Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking ImpairmentCompletedNCT03436199Phase 3Results posted
• Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHDCompletedNCT03247556Phase 3Results posted
• Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHDCompletedNCT03247543Phase 3Results posted
• Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHDCompletedNCT03247530Phase 3Results posted
• Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHDCompletedNCT03247517Phase 3Results posted
• A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)CompletedNCT02942017Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)CompletedNCT02942004Phase 3Results posted
• Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)TerminatedNCT02691182Phase 3Results posted
• Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHDCompletedNCT02633527Phase 2Results posted
• Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)CompletedNCT02618434Phase 3Results posted
• Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)CompletedNCT02618408Phase 3Results posted
• A Study to Evaluate SAGE-547 in Participants With Severe Postpartum DepressionCompletedNCT02614547Phase 2Results posted
• Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®TerminatedNCT02549573Phase 4Results posted
• A Study With SAGE-547 for Super-Refractory Status EpilepticusCompletedNCT02477618Phase 3Results posted
• Evaluate SAGE-547 in Female Participants With Severe Postpartum DepressionCompletedNCT02285504Phase 2Results posted
• Evaluate SAGE-547 in Participants With Essential TremorCompletedNCT02277106Phase 2Results posted
• Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced DyskinesiaCompletedNCT02274766Phase 3Results posted
• Open-Label Safety Study of ADS-5102 in PD Patients With LIDCompletedNCT02202551Phase 3Results posted
• Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.TerminatedNCT02153645Phase 3Results posted
• Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LIDTerminatedNCT02153632Phase 3Results posted
• ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)CompletedNCT02136914Phase 3Results posted
• Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status EpilepticusCompletedNCT02052739Phase 1/2Results posted
• Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)CompletedNCT01770145Phase 4Results posted
• Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)CompletedNCT01397422Phase 2/3Results posted
• Evaluation of Immediate-Release Viloxazine in Adults With ADHDCompletedNCT01107496Phase 1/2Results posted
• Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial EpilepsyCompletedNCT00908349Phase 3Results posted
• Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial SeizuresCompletedNCT00772603Phase 3Results posted
• Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct ProblemsCompletedNCT00626236Phase 2Results posted
• Mass Balance Study of NV-5138 in Healthy Male SubjectsCompletedNCT05384977Phase 1
• Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult SubjectsCompletedNCT05102552Early Phase 1
• Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric SubjectsWithdrawnNCT05097079Phase 3
• Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy ParticipantsCompletedNCT05049343Phase 1
• A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)WithdrawnNCT04273191Phase 4
• Classroom Study of SPN-812 in Children With ADHDWithdrawnNCT04016792Phase 3
• Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum DepressionApproved for marketingNCT03924492
• A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy SubjectsCompletedNCT03844906Phase 1
• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part BCompletedNCT03787758Phase 1
• A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy SubjectsCompletedNCT03771586Phase 1
• A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy SubjectsCompletedNCT03770780Phase 1
• Functional MRI Study in Healthy Children Engaged in Aggressive BehaviorsCompletedNCT03615703
• BIS-001-ER for the Treatment of Adult Focal Impaired Awareness SeizuresActive, not recruitingNCT03474770Phase 1/2
• Bioavailability, Safety, and Tolerability of BIS-001 ERCompletedNCT03156439Phase 1
• Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Active, not recruitingNCT02736656Phase 3
• Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking ImpairmentCompletedNCT02471222Phase 2
• An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status EpilepticusNo longer availableNCT02433314
• Infusion of Apomorphine: Long-term Safety StudyActive, not recruitingNCT02339064Phase 3
• Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810MCompletedNCT02023606Phase 1
• Open-Label, Extension Study to 810P202CompletedNCT01416064Phase 2
• A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT01364662Phase 2
• Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With EpilepsyCompletedNCT01284530Phase 1/2
• A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)CompletedNCT01114854Phase 1
• Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised SubjectsCompletedNCT00979251Phase 2
• Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy SubjectsApproved for marketingNCT00918424
• Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy PatientsCompletedNCT00918047Phase 1

← Supernus Pharmaceuticals, Inc. overview and focus areas